The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 744-747

  Tam, Vincent H ^a,b   Louie, Arnold ^a   Deziel, Mark R ^a   Liu, Weiguo ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GARENOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CULTURE MEDIUM; CURVE FITTING; DRUG EXPOSURE; HOLLOW FIBER; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TIME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; QUINOLINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 33846572283     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00334-06     Document Type: Article

References (12)

1. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38:1386-1391.
2. Bristol-Myers Squibb. 1999. Investigator brochure (BMS-284756). Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT.
3. Condra, J. H., and E. A. Emini. 1997. Preventing HIV-1 drug resistance. Sci. Med. 4:14-23.
4. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical simulations resource, University of Southern California, Los Angeles.
5. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
6. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
7. Jumbe, N. L., A. Louie, M. H. Miller, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, and G. L. Drusano. 2006. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:310-317.
8. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard, 6th ed. NCCLS, Wayne, PA.
9. Schmitz, F. J., B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, M. Klootwijk, J. Verhoef, A. Fluit, H. P. Heinz, K. Kohrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA, and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:481-484.
10. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, R. Leary, and G. L. Drusano. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.
11. Tam, V. H., A. N. Schilling, S. Neshat, K. Poole, D. A. Melnick, and E. A. Coyle. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927.
12. Walsh, C. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775-781.